News und Analysen
Gerresheimer AG: Gerresheimer und Portal schließen strategische Partnerschaft zur Entwicklung innovativer nadelfreier Injektionslösung für die Behandlung chronisch Erkrankter
DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das erste Quartal 2022
DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das erste Quartal 2022
DGAP-News: Evotec SE berichtet Ergebnisse für das erste Quartal 2022 am 11. Mai 2022
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 5. Mai 2022 zu den Ergebnissen für das erste Quartal 2022
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 5. Mai 2022 zu den Ergebnissen für das erste Quartal 2022
DGAP-Adhoc: QIAGEN N.V.: QIAGEN erhöht Ausblick für das Gesamtjahr 2022
DGAP-Adhoc: QIAGEN N.V.: QIAGEN erhöht Ausblick für das Gesamtjahr 2022
LivaNova to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald, Chief Executive Officer, will participate in discussions at the Piper
Novocure to Participate in Two Upcoming Investor Conferences
Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.
William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial
ICON Releases Environmental, Social and Governance Report
ICON plc (NASDAQ:ICLR) announced today the release of its 2020 Environmental, Social and Governance (ESG) Report. With the completion of ICON’s acquisition of PRA Health Sciences, the report
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Bronson Healthcare and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve Southwest Michigan
Bronson Healthcare and Acadia Healthcare Company today held a virtual groundbreaking ceremony marking the beginning of construction on the new hospital that the two companies are building together
PINC AI™ Applied Sciences (PAS) and Mölnlycke Health Care AB Clinical Trial Aims to Reduce Hospital-Acquired Infections (HAIs)
The PINC AI™ Applied Sciences (PAS) team, a division of PINC AI, the technology and services platform of Premier, Inc. (NASDAQ: PINC), and Mölnlycke, a world-leading medical solutions company
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 31 presentations on Tumor Treating Fields (TTFields) will be featured at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting from Nov. 18 to Nov. 21 in
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, has released updated data from the
LivaNova Comments on Decision by Court of Appeal of Milan
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commented on the decision delivered today by the Court of Appeal of Milan (CoA) for LivaNova to pay damages
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
Eastlake Behavioral Health Hospital Approved by Chula Vista Planning Commission
The Chula Vista Planning Commission today approved a new inpatient behavioral health hospital in the Eastlake community of Chula Vista. The Eastlake behavioral health hospital will be operated by a
ICON Announces the Expansion of its Accellacare Site Network
ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, today announced that
LivaNova to Present at the 2021 Stifel and Jefferies Healthcare Conferences
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported